Namisaki T - Search Results

1

A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.

Yagi M, Matsumoto K, Komori A, Abe M, Hashimoto N, Inao M, Namisaki T, Kawata K, Ninomiya M, Fujii H, Takahashi A, Kang JH, Takamura M, Arakawa M, Joshita S, Sato K, Itakura J, Nomura T, Kakisaka K, Kaneko A, Tamura Y, Miura R, Aiso M, Arizumi T, Asaoka Y, Kikuchi K, Takikawa Y, Masaki T, Umemura T, Honda A, Ohira H, Kawada N, Yoshiji H, Mochida S, Takikawa H, Tanaka A; Japan PBC Study Group (JPBCSG). Yagi M, et al. Among authors: namisaki t. Liver Int. 2020 Aug;40(8):1926-1933. doi: 10.1111/liv.14534. Epub 2020 May 30. Liver Int. 2020. PMID: 32438508

2

Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model.

Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H. Ikenaka Y, et al. Among authors: namisaki t. Int J Cancer. 2003 Jun 20;105(3):340-6. doi: 10.1002/ijc.11094. Int J Cancer. 2003. PMID: 12704667 Free article.

3

Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.

Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T, Fukui H. Noguchi R, et al. Among authors: namisaki t. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6038-45. Clin Cancer Res. 2003. PMID: 14676130

4

Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.

Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H. Yoshiji H, et al. Among authors: namisaki t. Hepatology. 2004 Jun;39(6):1517-24. doi: 10.1002/hep.20218. Hepatology. 2004. PMID: 15185292

5

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H. Yoshiji H, et al. Among authors: namisaki t. Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13. doi: 10.1152/ajpgi.00420.2004. Epub 2004 Dec 23. Am J Physiol Gastrointest Liver Physiol. 2005. PMID: 15618280 Free article.

6

Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development.

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Fukui H. Yoshiji H, et al. Among authors: namisaki t. Liver Int. 2005 Feb;25(1):153-61. doi: 10.1111/j.1478-3231.2005.01038.x. Liver Int. 2005. PMID: 15698413

7

Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T, Fukui H. Yoshiji H, et al. Among authors: namisaki t. J Hepatol. 2005 May;42(5):687-93. doi: 10.1016/j.jhep.2004.12.025. J Hepatol. 2005. PMID: 15826718

8

Intrahepatic cholangiocarcinoma associated with central calcification and arterio-portal shunt.

Kitade M, Yoshiji H, Yamao J, Fujimoto M, Kojima H, Mitoro A, Yoshida M, Namisaki T, Yamazaki M, Toyohara M, Uemura M, Fukui H. Kitade M, et al. Among authors: namisaki t. Intern Med. 2005 Aug;44(8):825-8. doi: 10.2169/internalmedicine.44.825. Intern Med. 2005. PMID: 16157980 Free article.

9

Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.

Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H. Noguchi R, et al. Among authors: namisaki t. Oncol Rep. 2009 Aug;22(2):355-60. Oncol Rep. 2009. PMID: 19578777

10

Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.

Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamazaki M, Namisaki T, Kitade M, Yoshii J, Yanase K, Kawaratani H, Tsujimoto T, Fukui H. Noguchi R, et al. Among authors: namisaki t. Int J Mol Med. 2010 Sep;26(3):407-13. Int J Mol Med. 2010. PMID: 20664958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

176 results

Search Page